Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
76.35
+0.55 (+0.73%)
Official Closing Price
Updated: 4:15 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks
April 06, 2022
From
AstraZeneca
Via
Business Wire
AstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees
March 24, 2022
From
AstraZeneca
Via
Business Wire
EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies
March 21, 2022
From
AstraZeneca
Via
Business Wire
LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer
March 16, 2022
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast Cancer
February 21, 2022
From
AstraZeneca
Via
Business Wire
LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer
February 14, 2022
From
AstraZeneca
Via
Business Wire
Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
January 24, 2022
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years
January 18, 2022
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer
January 18, 2022
From
AstraZeneca
Via
Business Wire
CORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
January 17, 2022
From
AstraZeneca
Via
Business Wire
Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based Regimen
January 17, 2022
From
AstraZeneca
Via
Business Wire
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
January 14, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 14, 2022 – USA News Group – Cancer cases are on the rise, according to a new study comparing the number of cancer...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
AstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI® (durvalumab) and LYNPARZA® (olaparib) Data at ASCO GI and GU
January 13, 2022
From
AstraZeneca
Via
Business Wire
TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma
January 13, 2022
From
AstraZeneca
Via
Business Wire
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities
December 23, 2021
From
AstraZeneca
Via
Business Wire
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study
December 16, 2021
From
AstraZeneca
Via
Business Wire
CALQUENCE reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial
December 12, 2021
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Additional Analyses Further Reinforce Ground-breaking Efficacy in Patients With HER2-positive Metastatic Breast Cancer
December 09, 2021
From
AstraZeneca
Via
Business Wire
EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19
December 08, 2021
From
AstraZeneca
Via
Business Wire
AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care
December 03, 2021
From
AstraZeneca
Via
Business Wire
LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer
November 30, 2021
From
AstraZeneca
Via
Business Wire
New Analyses of Two AZD7442 COVID-19 Phase III Trials in High-Risk Populations Confirm Robust Efficacy and Long-Term Prevention
November 18, 2021
From
AstraZeneca
Via
Business Wire
LOKELMA® Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia
November 17, 2021
From
AstraZeneca
Via
Business Wire
AstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021
November 05, 2021
From
AstraZeneca
Via
Business Wire
SAPHNELO Consistently Reduces Systemic Lupus Erythematosus Disease Activity Regardless of Disease Duration and Prior Treatment
November 01, 2021
From
AstraZeneca
Via
Business Wire
Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027
November 03, 2021
Palm Beach, FL – November 3, 2021 – FinancialNewsMedia.com News Commentary – The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast,...
Via
FinancialNewsMedia
AstraZeneca Awards 30 Nonprofit Organizations through the ACT on Health Equity Community Solutions Challenge to Actively Address Health Disparities
November 01, 2021
From
AstraZeneca
Via
Business Wire
IMFINZI Plus Chemotherapy Significantly Improved Overall Survival in 1st-Line Advanced Biliary Tract Cancer in TOPAZ-1 Phase III Trial at Interim Analysis
October 25, 2021
From
AstraZeneca
Via
Business Wire
AstraZeneca Announces Winners and Recognizes Oncology Change Makers in Third Annual Cancer Community Awards
October 20, 2021
From
AstraZeneca
Via
Business Wire
IMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer
October 15, 2021
From
AstraZeneca
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.